Evidence map›Paper›PMID 35038960›Full record

ArticleBioengineered2022

Effects of I125 seed stent implantation combined with arterial infusion chemoembolization on tumor markers, p53 expression, and prognosis in patients with cholangiocarcinoma.

Zhe Xu, Minglin Xu, Meng Li, Zhe Cui, Haisheng Bai, Heqing Shang, Jianyu Zhao, Lei Wu, Fan Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Zhe XuDepartment of Interventional Therapy, Hulunbuir People's Hospital, Inner Mongolia China.
Minglin XuDepartment of Interventional Therapy, Hulunbuir People's Hospital, Inner Mongolia China.
Meng LiDepartment of Interventional Therapy, Hulunbuir People's Hospital, Inner Mongolia China.
Zhe CuiDepartment of Interventional Therapy, Hulunbuir People's Hospital, Inner Mongolia China.
Haisheng BaiDepartment of Interventional Therapy, Hulunbuir People's Hospital, Inner Mongolia China.
Heqing ShangDepartment of Interventional Therapy, Hulunbuir People's Hospital, Inner Mongolia China.
Jianyu ZhaoDepartment of Interventional Therapy, Hulunbuir People's Hospital, Inner Mongolia China.
Lei WuDepartment of Interventional Therapy, Hulunbuir People's Hospital, Inner Mongolia China.
Fan ZhangDepartment of Reproductive Center, Hulunbuir People's Hospital, Inner Mongolia China.
Hulunbuir University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholangiocarcinoma is a common malignant tumor. Advanced treatment is difficult and the prognosis is poor. It is of great significance to find an effective method to treat cholangiocarcinoma and improve the prognosis of patients. Therefore, 78 patients with cholangiocarcinoma treated in our hospital were divided into group A and group B according to different treatment methods. The clinical effect, bilirubin, tumor size, bile duct patency time, tumor marker level To evaluate the therapeutic effect of I125 seed stent implantation combined with arterial infusion chemoembolization in patients with cholangiocarcinoma. The results showed that I125 seed stent implantation combined with TACE in the treatment of patients with cholangiocarcinoma can play an obvious clinical effect, effectively reduce the level of tumor markers and p53, reduce tumor lesions, improve the survival rate of patients, and play an important role in tumor treatment.

Indexed as

Drug-Eluting StentsAdultAgedAged, 80 and overBile Duct NeoplasmsBile Ducts, IntrahepaticBiomarkers, TumorChemoembolization, TherapeuticChinaCholangiocarcinomaCombined Modality TherapyFemaleHumansIodine RadioisotopesMaleMiddle AgedBiomarkers, TumorIodine-125Iodine RadioisotopesTumor Suppressor Protein p53arterial infusion chemoembolizationcholangiocarcinomaI125 particle stent

Identifiers

PMID35038960
PMCPMC8974219
OpenAlexW4206651999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.